[go: up one dir, main page]

WO2009031635A1 - 腎性尿崩症治療用組換えベクター及びその用途 - Google Patents

腎性尿崩症治療用組換えベクター及びその用途 Download PDF

Info

Publication number
WO2009031635A1
WO2009031635A1 PCT/JP2008/066034 JP2008066034W WO2009031635A1 WO 2009031635 A1 WO2009031635 A1 WO 2009031635A1 JP 2008066034 W JP2008066034 W JP 2008066034W WO 2009031635 A1 WO2009031635 A1 WO 2009031635A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes insipidus
treatment
nephrogenic diabetes
recombinant vector
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066034
Other languages
English (en)
French (fr)
Inventor
Hiroshi Nagasaki
Hidetaka Suga
Yutaka Oiso
Mamoru Hasegawa
Makoto Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya University NUC
Original Assignee
Nagoya University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya University NUC filed Critical Nagoya University NUC
Publication of WO2009031635A1 publication Critical patent/WO2009031635A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　腎性尿崩症に対する新たな治療法を創出することを課題とする。アクアポリン２遺伝子を保持する腎性尿崩症治療用組換えベクターが提供される。好ましい一態様では、ベクターとしてセンダイウイルスベクターを用いる。
PCT/JP2008/066034 2007-09-07 2008-09-05 腎性尿崩症治療用組換えベクター及びその用途 Ceased WO2009031635A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-232310 2007-09-07
JP2007232310 2007-09-07

Publications (1)

Publication Number Publication Date
WO2009031635A1 true WO2009031635A1 (ja) 2009-03-12

Family

ID=40428947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066034 Ceased WO2009031635A1 (ja) 2007-09-07 2008-09-05 腎性尿崩症治療用組換えベクター及びその用途

Country Status (2)

Country Link
JP (1) JP2009079042A (ja)
WO (1) WO2009031635A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021043340A3 (zh) * 2019-09-05 2021-04-22 南京安吉生物科技有限公司 一种肿瘤标志物aquaporin 2蛋白及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2564900C2 (ru) * 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
JP6402667B2 (ja) * 2015-03-27 2018-10-10 株式会社豊田中央研究所 生体適合性液体及びそのスクリーニング方法
CN109266616A (zh) * 2018-08-21 2019-01-25 山西省人民医院 一种稳定表达aqp2蛋白的人源化小鼠足细胞模型及其构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000264A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for transferring gene into renal cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000264A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for transferring gene into renal cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIROSHI ARIMA ET AL.: "Nyohosho Chiryo no Tenbo", SAISHIN IGAKU, vol. 57, no. 12, 2002, pages 2694 - 2699 *
KATSURA, T. ET AL.: "Constitutive and regulated membrane expression of aquaporin 1 and aquaporin 2 water channels in stably transfected LLC- PK 1 epitherial cells", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 7212 - 7216, XP055354079 *
SUGA, H. ET AL.: "Novel treatment for lithium induced nephrogenic diabetes insipidus rat model using the sendai-virus vector carrying aquaporin 2 gene", ENDOCRINOLOGY, 24 July 2008 (2008-07-24), Retrieved from the Internet <URL:http://endo. endojournals.org/cgi/rapidpdf/en.2007-1806v1> [retrieved on 20081027] *
VERKMAN, A.S. ET AL.: "Aquaporin gene delivery to kidney", KIDNEY INT., vol. 61, 2002, pages S-120 - S-124 *
YANG, B. ET AL.: "Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus", J. BIOL. CHEM., vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2775 - 2779, XP055354074 *
YUTAKA OISO: "Idensei Nyohosho Hassho ni Kansuru Bunshi Kiko", IGAKU NO AYUMI, vol. 213, no. 5, 30 April 2005 (2005-04-30), pages 342 - 346 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021043340A3 (zh) * 2019-09-05 2021-04-22 南京安吉生物科技有限公司 一种肿瘤标志物aquaporin 2蛋白及其应用

Also Published As

Publication number Publication date
JP2009079042A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
AU2010327993A8 (en) 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters
SG195194A1 (en) Nanogels
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2012170911A3 (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
EP2273975B8 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
WO2010068862A3 (en) Zwitterionic polymers with therapeutic moieties
EP2315833B8 (en) Vectors for delivery of light-sensitive proteins and methods of use
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
EP2614418A4 (en) Method of operating mobile device by recognizing user&#39;s gesture and mobile device using the method
NZ616989A (en) Therapeutic nuclease compositions and methods
NZ603623A (en) Tcr complex immunotherapeutics
JP2014501492A5 (ja)
WO2010022195A3 (en) Non-integrating lenti/adeno-associated virus hybrid vector system
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
WO2007106022A3 (en) A new crystalline form g of (5s) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (i) and intermediates thereof.
WO2013036622A3 (en) Antiviral peptides effective against hepatitis c virus
WO2009031635A1 (ja) 腎性尿崩症治療用組換えベクター及びその用途
WO2013006692A3 (en) Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
WO2009111336A3 (en) Methods of purifying plasmid dna
WO2012010976A3 (en) Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
WO2011051916A3 (en) Stabilized protein formulations and use thereof
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
NZ599521A (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08829025

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08829025

Country of ref document: EP

Kind code of ref document: A1